{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T06:01:24Z","timestamp":1772431284168,"version":"3.50.1"},"reference-count":35,"publisher":"Japan Atherosclerosis Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.5551\/jat.41343","type":"journal-article","created":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T22:14:22Z","timestamp":1512166462000},"page":"512-520","source":"Crossref","is-referenced-by-count":23,"title":["Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)"],"prefix":"10.5551","volume":"25","author":[{"given":"Daisaku","family":"Masuda","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"},{"name":"Rinku General Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"},{"name":"Rinku General Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Sairyou","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Hanada","sequence":"additional","affiliation":[{"name":"Division of Laboratory for Clinical Investigation, Department of Medical Technology, Osaka University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Ohama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"},{"name":"Department of Dental Anesthesiology, Osaka University Graduate School of Dentistry"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Koseki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"},{"name":"Health Care Center, Osaka University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"},{"name":"Health Care Center, Osaka University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norikazu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Kihara","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine"},{"name":"Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Minami","sequence":"additional","affiliation":[{"name":"Souseikai Sousei Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Yanagi","sequence":"additional","affiliation":[{"name":"Osaka Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuya","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Osaka University Graduate School of Medicine"},{"name":"Rinku General Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Hata J, Ninomiya T, Hirakawa Y, Nagata M, Mukai N, Gotoh S, Fukuhara M, Ikeda F, Shikata K, Yoshida D, Yonemoto K, Kamouchi M, Kitazono T, Kiyohara Y: Secular trends in cardiovascular disease and its risk factors in Japanese: half-century data from the Hisayama Study (1961-2009). Circulation, 2013; 128: 1198-1205","DOI":"10.1161\/CIRCULATIONAHA.113.002424"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Haffner SM, Lehto S, R\u00f6nnemaa T, Py\u00f6r\u00e4l\u00e4 K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 39(4): 229-234","DOI":"10.1056\/NEJM199807233390404"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Masuda D, Yamashita S: Postprandial hyperlipidemia and remnant lipoproteins. J Atheroscler Thromb, 2017; 24: 95-109","DOI":"10.5551\/jat.RV16003"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, Mundl H, Olsson AG: Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol, 2015; 65: 2267-2275","DOI":"10.1016\/j.jacc.2015.03.544"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Watanabe N, Taniguchi T, Taketoh H, Kitagawa Y, Namura H, Yoneda N, Kurimoto Y, Yamada S, Ishikawa Y: Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Diabetes Care, 1999; 22: 152-156","DOI":"10.2337\/diacare.22.1.152"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Syv\u00e4nne M, Taskinen MR: Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. 1997; 350: S20-S23","DOI":"10.1016\/S0140-6736(97)90024-6"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A: Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res, 2001; 42: 17-21","DOI":"10.1016\/S0022-2275(20)32331-2"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, Tsunoda R, Sakamoto T, Nakano T, Nakajima K, Ogawa H, Sugiyama S, Yoshimura M, Yasue H: Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation, 1999; 99(22): 2858-2860","DOI":"10.1161\/01.CIR.99.22.2858"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Curtin A, Deegan P, Owens D, Collins P, Johnson A, Tomkin GH: Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48. Acta Diabetol, 1996; 33: 205-210","DOI":"10.1007\/BF02048544"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ai M, Tanaka A, Ogita K, Sekinc M, Numano FF, Numano FF, Reaven GM: Relationship between plasma insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes. J Am Coll Cardiol, 2001; 38: 1628-1632","DOI":"10.1016\/S0735-1097(01)01611-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complications Study Group: Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab, 2011; 96: 3448-3456","DOI":"10.1210\/jc.2011-0622"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Fuller JH, Fuller JH1, Stevens LK, Wang SL: Risk factors for cardiovascular mortality and morbidity: the WHO Mutinational Study of Vascular Disease in Diabetes. Diabetologia, 2001; 44 Suppl 2: S54-64","DOI":"10.1007\/PL00002940"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Son JW, Kim S: Dipeptidyl peptidase 4 inhibitors and the risk of cardiovascular disease in patients with type 2 diabetes: A tale of three studies. Diabetes Metab J, 2015; 39: 373-383","DOI":"10.4093\/dmj.2015.39.5.373"},{"key":"14","unstructured":"14) Okazaki M, Usui S, Hosaki S: Analysis of plasma lipoproteins by gel permeation chromatography. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing. Washington, DC: AACC Press. pp. 647- 669"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K; Japan Atherosclerosis Society: Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. J Atheroscler Thromb, 2013; 20: 517-523","DOI":"10.5551\/jat.15792"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR on behalf of the UK Prospective Diabetes Study Group: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000; 321: 405-412","DOI":"10.1136\/bmj.321.7258.405"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV: Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins C-III and AI. Evidence that apolipoprotein C-III inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest, 1986; 78: 1287-1295","DOI":"10.1172\/JCI112713"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Windler E, Havel RJ: Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceriderich lipoproteins and their remnants by the perfused rat liver. J Lipid Res, 1985; 26: 556-565","DOI":"10.1016\/S0022-2275(20)34342-X"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH: Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest, 2004; 114: 1493-1503","DOI":"10.1172\/JCI200419992"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Caron S, Verrijken A, Mertens I, Samanez CH, Mautino G, Haas JT, Duran-Sandoval D, Prawitt J, Francque S, Vallez E, Muhr-Tailleux A, Berard I, Kuipers F, Kuivenhoven JA, Biddinger SB, Taskinen MR, Van Gaal L, Staels B: Transcriptional activation of apolipoprotein C-III expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol, 2011; 31: 513-519","DOI":"10.1161\/ATVBAHA.110.220723"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kawakami A, Osaka M, Tani M, Azuma H, Sacks FM, Shimokado K, Yoshida M: Apolipoprotein C-III links hyperlipidemia with vascular endothelial cell dysfunction. Circulation, 2008; 118: 731-742","DOI":"10.1161\/CIRCULATIONAHA.108.784785"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Adeli K, Lewis GF: Intestinal lipoprotein overproduction in insulin-resistant states. Curr Opin Lipidol, 2008; 19: 221-228","DOI":"10.1097\/MOL.0b013e3282ffaf82"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF: Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler Thromb Vasc Biol, 2006; 26: 1357-1363","DOI":"10.1161\/01.ATV.0000222015.76038.14"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P: Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes. J Lipid Res, 2007; 48: 1336-1342","DOI":"10.1194\/jlr.M600548-JLR200"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Hsieh J, Longuet C, Baker CL, Qin B, Federico LM, Drucker DJ, Adeli K: The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia, 2010; 53: 552-561","DOI":"10.1007\/s00125-009-1611-5"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Qin X, Shen H, Liu M, Yang Q, Zheng S, Sabo M, D'Alessio DA, Tso P: GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol, 2005; 288: G943-949","DOI":"10.1152\/ajpgi.00303.2004"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Hermansen K, B\u00e6kdal TA, D\u00fcring M, Pietraszek A, Mortensen LS, J\u00f8rgensen H, Flint A: Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab, 2013; 15: 1040-1048","DOI":"10.1111\/dom.12133"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Meier JJ, Gethmann A, G\u00f6tze O, Gallwitz B, Holst JJ, Schmidt WE, Nauck MA: Glucagon-like peptide 1 abol ishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia, 2006; 49: 452-458","DOI":"10.1007\/s00125-005-0126-y"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P: Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab, 2011; 13: 366-373","DOI":"10.1111\/j.1463-1326.2011.01362.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Matikainen N, M\u00e4ntt\u00e4ri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR: Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia, 2006; 49: 2049-2057","DOI":"10.1007\/s00125-006-0340-2"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Boschmann M, Engeli S, Dobberstein K, Budziarek P, Strauss A, Boehnke J, Sweep FC, Luft FC, He Y, Foley JE, Jordan J: Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab, 2009; 94: 846-852","DOI":"10.1210\/jc.2008-1400"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Yang TY, Liaw YP, Huang JY, Chang HR, Chang KW, Ueng KC: Association of Sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study. Acta Diabetol, 2016; 53(3): 461-468","DOI":"10.1007\/s00592-015-0817-x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators: Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med, 2015; 373: 2247-2257","DOI":"10.1056\/NEJMoa1509225"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators: Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2016; 375: 311-322","DOI":"10.1056\/NEJMoa1603827"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Tanaka S, Kanazawa I, Notsu M, Sugimoto T: Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus. Diabetes Res Clin Pract, 2016; 116: 1-6","DOI":"10.1016\/j.diabres.2016.04.027"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/25\/6\/25_41343\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T20:40:59Z","timestamp":1660077659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/25\/6\/25_41343\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.41343","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}